@article {7685, title = {The combination of N-acetyl cysteine, alpha-lipoic acid, and bromelain shows high anti-inflammatory properties in novel in vivo and in vitro models of endometriosis.}, journal = {Mediators Inflamm}, volume = {2015}, year = {2015}, month = {2015}, pages = {918089}, abstract = {

To evaluate the efficacy of an association of N-acetyl cystein, alpha-lipoic acid, and bromelain (NAC/LA/Br) in the treatment of endometriosis we set up a new in vivo murine model. We explored the anti-inflammatory and proapoptotic effect of this combination on human endometriotic endothelial cells (EECs) and on endothelial cells isolated from normal uterus (UtMECs). We implanted fragments of human endometriotic cysts intraperitoneally into SCID mice to evaluate the efficacy of NAC/LA/Br treatment. UtMECs and EECs, untreated or treated with NAC/LA/Br, were activated with the proinflammatory stimulus TNF-α and their response in terms of VCAM1 expression was evaluated. The proapoptotic effect of higher doses of NAC/LA/Br on UtMECs and EECs was measured with a fluorogenic substrate for activated caspases 3 and 7. The preincubation of EECs with NAC/LA/Br prior to cell stimulation with TNF-α prevents the upregulation of the expression of the inflammatory "marker" VCAM1. Furthermore NAC/LA/Br were able to induce EEC, but not UtMEC, apoptosis. Finally, the novel mouse model allowed us to demonstrate that mice treated with NAC/LA/Br presented a lower number of cysts, smaller in size, compared to untreated mice. Our findings suggest that these dietary supplements may have potential therapeutic uses in the treatment of chronic inflammatory diseases like endometriosis.

}, issn = {1466-1861}, doi = {10.1155/2015/918089}, author = {Agostinis, C and Zorzet, S and De Leo, R and Zauli, G and De Seta, F and Bulla, R} } @article {1959, title = {State of the art of the therapeutic perspective of sorafenib against hematological malignancies.}, journal = {Curr Med Chem}, volume = {19}, year = {2012}, month = {2012}, pages = {4875-84}, abstract = {

The bi-aryl urea multi-kinase inhibitor Sorafenib (BAY 43-9006, Nexavar) was initially approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Eleven years after its first description in PubMed, the therapeutic potential of Sorafenib has been evaluated in an increasing number of studies, mainly focused on solid tumors. More recently, the potential usefullness of Sorafenib has started to emerge also against hematological malignancies. At the molecular level, besides the RAF kinase pathway, which represents the first therapeutic target of Sorafenib, additional kinases, in particular the vascular endothelial growth factor receptor, have been identified as important targets of Sorafenib. A great interest for the potential use of Sorafenib against acute myeloid leukemia (AML) arose when it was demonstrated that a specific mutation of a kinase gene, called FMS-like tyrosin-kinase-3- internal tandem duplication (FLT-3-ITD) and occurring in more than 30\% of AML, represents a molecular target of Sorafenib. However, recent phase I and II clinical studies showed that, in spite of its ability to suppress the activity of this mutated kinase, resistence to Sorafenib rapidly occurs in AML, suggesting that Sorafenib will be more effective in combined therapy than used as single drug. Another critical molecular target of Sorafenib is the anti-apoptotic protein Mcl-1. The ability of Sorafenib to rapidly shut-off Mcl-1 in virtually all the hematological malignancies investigated, including the B-chronic lymphocytic leukemia, represents a key element for its antileukemic activity as well as for therapeutic combinations based on Sorafenib. In this respect, it is of particular interest that many chemotherapeutic drugs or innovative anti-neoplastic compounds, such as recombinant TRAIL or inibitors of MDM2 protein, are either unable to down-regulate Mcl-1 or in some instances promote a paradoxical induction of Mcl-1. In this review, the growing evidences for the role of Mcl-1 in mediating the anti-leukemic activity of Sorafenib will be discussed in relationship with promising therapeutic perspectives.

}, keywords = {Apoptosis, Clinical Trials as Topic, fms-Like Tyrosine Kinase 3, Hematologic Neoplasms, Humans, Leukemia, Myeloid, Acute, Myeloid Cell Leukemia Sequence 1 Protein, Niacinamide, Phenylurea Compounds, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-mdm2, Receptors, Vascular Endothelial Growth Factor, TNF-Related Apoptosis-Inducing Ligand}, issn = {1875-533X}, author = {Zauli, G and Voltan, R and Tisato, V and Secchiero, P} } @article {1803, title = {Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy.}, journal = {Diabet Med}, volume = {28}, year = {2011}, month = {2011 Oct}, pages = {1277-8}, keywords = {Apoptosis Regulatory Proteins, Body Fluids, Conjunctiva, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Receptors, TNF-Related Apoptosis-Inducing Ligand, TNF-Related Apoptosis-Inducing Ligand}, issn = {1464-5491}, doi = {10.1111/j.1464-5491.2010.03202.x}, author = {Secchiero, P and Perri, P and Melloni, E and Martini, A and Lamberti, G and Sebastiani, A and Zauli, G} } @article {1740, title = {Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.}, journal = {Mini Rev Med Chem}, volume = {11}, year = {2011}, month = {2011 Mar}, pages = {185-99}, abstract = {

The serine/threonine protein kinase C (PKC) family was first identified as intracellular receptor(s) for the tumor promoting agents phorbol esters. Thirty years after the discovery of PKC, the role of specific PKC isoforms has been described in relationship with an altered pattern of expression in different types of cancer and a good number of small molecule inhibitors (inhibitory peptides, antisense oligonucleotides or natural compounds) targeting PKC are now available. Despite all these achievements and a huge amount of basic research studies on the biochemical regulation of PKC, there has been a delay in clinical trials with drugs targeting PKC function. This delay is easily explained taking into account the extreme biological complexity of the PKC family of isoforms and the incomplete understanding of the specific role of each PKC isozyme in different types of cancers. Some of the difficulties in developing pharmacological compounds selectively tuning the different PKCs have started to be overcome. In this review, the growing evidences of the role of the PKC isoforms α, βII, δ, ε, ζ and ι is in promoting or counteracting tumor progression will be discussed in relationship with promising therapeutic perspectives.

}, keywords = {Antineoplastic Agents, Biological Products, Enzyme Inhibitors, Humans, Isoenzymes, Neoplasms, Oligonucleotides, Antisense, Peptides, Protein Kinase C}, issn = {1875-5607}, author = {Bosco, R and Melloni, E and Celeghini, C and Rimondi, E and Vaccarezza, M and Zauli, G} } @article {1788, title = {TRAIL promotes a pro-survival signal in erythropoietin-deprived human erythroblasts through the activation of an NF-kB/IkBalpha pathway.}, journal = {J Biol Regul Homeost Agents}, volume = {25}, year = {2011}, month = {2011 Jul-Sep}, pages = {375-86}, abstract = {

The biological activity of TNF-related apoptosis inducing ligand (TRAIL) was analyzed in primary human erythroblasts derived from mononuclear cells of blood donors, kept in culture in the presence of 20 percent foetal calf serum, growth factors (EPO, SCF, IL-3) and glucocorticoids (10-6 M dexamethasone, 10-6 M oestradiol) or under growth factor and serum starvation. In the presence of growth factors and serum, primary erythroblasts showed a differential expression of TRAIL-Receptors (Rs) at various degrees of maturation and responded to TRAIL treatment with a mild cytotoxicity. On the other hand, in the absence of serum and growth factors, TRAIL treatment unexpectedly up-regulated TRAIL-R4 decoy receptor and promoted erythroblast survival. The concomitant activation of NF-kB/IkB survival pathway was detected with Western blotting and immunofluorescence procedures and confirmed by experiments performed with SN50, a pharmacological inhibitor of the NF-kB/IkB pathway. Our study indicates that TRAIL has a twofold activity on erythroid lineages: it induces a mild erythroid cell cytotoxicity in the presence of serum and growth factors, while it promotes erythroid cell survival through the activation of the NF-kB/IkB pathway under starvation conditions.

}, keywords = {Cell Survival, Erythroblasts, Erythropoietin, Gene Expression Regulation, Humans, I-kappa B Kinase, Jurkat Cells, NF-kappa B, Peptides, TNF-Related Apoptosis-Inducing Ligand, Tumor Necrosis Factor Decoy Receptors}, issn = {0393-974X}, author = {Sancilio, S and Di Giacomo, V and Quaglietta, A M and Iacone, A and Angelucci, D and Tatasciore, U and Rana, R A and Cataldi, A and Zauli, G and Di Pietro, R} }